LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Akcijų sąrašas・Exelixis Inc

Search

Exelixis Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

52.45 -0.98

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

52.29

Max

53.79

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-34M 210M
Pardavimai	12M 611M
P/E Sektoriaus vid.	17.48 49.052
Pelnas, tenkantis vienai akcijai	0.87
Pelno marža	34.457
Darbuotojai	1,077
EBITDA	15M 258M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	-9.98% downside

Dividendai
By Dow Jones
Kitas uždarbis	2026-07-27

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1.8B 13B
Ankstesnė atidarymo kaina	53.43
Ankstesnė uždarymo kaina	52.45

Exelixis Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-10 23:36; UTC

Uždarbis

Correction to Oracle Reports Higher 4Q Profit Article

2026-06-10 23:19; UTC

Karštos akcijos

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

2026-06-10 23:09; UTC

Pagrindinės rinkos jėgos

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

2026-06-10 23:04; UTC

Uždarbis

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

2026-06-10 20:44; UTC

Pagrindinės rinkos jėgos

Caterpillar Raises Quarterly Dividend 8%

2026-06-10 23:49; UTC

Įsigijimai, susijungimai, perėmimai

Elliott: Northern Star Should Take No Options Off The Table

2026-06-10 23:48; UTC

Įsigijimai, susijungimai, perėmimai

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

2026-06-10 23:48; UTC

Įsigijimai, susijungimai, perėmimai

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

2026-06-10 23:47; UTC

Rinkos pokalbiai

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

2026-06-10 23:47; UTC

Įsigijimai, susijungimai, perėmimai

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

2026-06-10 23:46; UTC

Įsigijimai, susijungimai, perėmimai

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

2026-06-10 23:38; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-06-10 23:38; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-10 23:38; UTC

Rinkos pokalbiai

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

2026-06-10 23:32; UTC

Rinkos pokalbiai

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

2026-06-10 23:20; UTC

Rinkos pokalbiai

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

2026-06-10 22:05; UTC

Rinkos pokalbiai

Correction to Bank of Canada Stays on Hold Market Talk

2026-06-10 21:57; UTC

Uždarbis

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026-06-10 21:52; UTC

Uždarbis

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026-06-10 21:35; UTC

Uždarbis

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026-06-10 21:22; UTC

Uždarbis

Oracle Stock Slides on Increased Capital Spending -- WSJ

2026-06-10 20:50; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2026-06-10 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-10 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-06-10 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-06-10 20:39; UTC

Rinkos pokalbiai

Uždarbis

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

2026-06-10 20:34; UTC

Uždarbis

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026-06-10 20:33; UTC

Uždarbis

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

2026-06-10 20:33; UTC

Rinkos pokalbiai

Uždarbis

Global Equities Roundup: Market Talk

2026-06-10 20:33; UTC

Rinkos pokalbiai

Uždarbis

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Akcijų palyginimas

Kainos pokytis

Exelixis Inc Prognozė

Kainos tikslas

By TipRanks

-9.98% į apačią

12 mėnesių prognozė

Vidutinis 47.7 USD -9.98%

Aukščiausias 56 USD

Žemiausias 40 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Exelixis Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

5

Pirkti

6

Laikyti

0

Parduoti

Remiantis 11 analitikų, pateikusių Exelixis Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Exelixis Inc

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Kitos sektoriaus akcijos

LLY

Eli Lilly and Co.

1,136.41

JNJ

Johnson and Johnson

238.85

ABBV

AbbVie Inc

225.29

UNH

UnitedHealth Group Inc

407.06

MRK

Merck & Co Inc.

119

Live chat